Open Forum Infectious Diseases Advance Access published December 8, 2016
Using Procalcitonin to Guide Antibiotic Therapy Chanu Rhee, MD, MPH1,2 Author Affiliations:
cr ip t
1. Department of Population Medicine, Harvard Medical School / Harvard Pilgrim Health Care Institute, Boston MA
2. Division of Infectious Diseases, Brigham and Women’s Hospital, Boston MA
an
Address: Department of Population Medicine
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, MA 02215
M
401 Park Drive, Suite 401
Phone: 617-509-9987, Fax: 617-859-8112
d
Keywords: procalcitonin; antibiotic stewardship; biomarkers; respiratory infections; sepsis
pt e
Running title: Procalcitonin-guided antibiotic therapy Manuscript Word Count: 3507 words
ce
Key Points (39/40 words): Procalcitonin can guide early antibiotic discontinuation and the decision to withhold antibiotics altogether in stable patients with suspected respiratory
Ac
infections. In critically ill patients with suspected or proven infection, serial procalcitonin measurements can guide antibiotic discontinuation after clinical stabilization.
1
© The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact
[email protected].
Downloaded from http://ofid.oxfordjournals.org/ by guest on December 9, 2016
Chanu Rhee, MD, MPH (
[email protected])
us
Corresponding Author:
Abstract (150/150 Words)
Procalcitonin levels rise in response to systemic inflammation, especially of bacterial origin.
cr ip t
Multiple randomized controlled trials have demonstrated that procalcitonin-based algorithms can safely reduce antibiotic use in two clinical scenarios. First, in stable, low-risk patients with
respiratory infections, procalcitonin levels of
